Compare ARKO & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARKO | OLMA |
|---|---|---|
| Founded | 1970 | 2006 |
| Country | United States | United States |
| Employees | 9748 | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 863.8M | 994.9M |
| IPO Year | N/A | 2020 |
| Metric | ARKO | OLMA |
|---|---|---|
| Price | $8.00 | $11.69 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | $7.50 | ★ $44.89 |
| AVG Volume (30 Days) | 690.9K | ★ 1.5M |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.91% | N/A |
| EPS Growth | N/A | ★ 15.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.86 | N/A |
| Revenue Next Year | $1.49 | N/A |
| P/E Ratio | $56.88 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.71 | $4.47 |
| 52 Week High | $8.76 | $36.26 |
| Indicator | ARKO | OLMA |
|---|---|---|
| Relative Strength Index (RSI) | 51.64 | 49.70 |
| Support Level | $7.44 | $7.79 |
| Resistance Level | $7.95 | $13.09 |
| Average True Range (ATR) | 0.32 | 0.65 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 51.64 | 40.76 |
ARKO Corp owns and operates convenience stores in the United States. Some of its regional store brands include Stop, Admiral, Apple Market, BreadBox, E-Z Mart, fas mart, Li'l Cricket, and Next Door Store. Its retail store offers hot food service, beverages, cigarettes & other tobacco products, candy, salty snacks, grocery, beer, and general merchandise. ARKO operates in four segments: Retail segment, Wholesale segment, fleet fueling segment, and GPM Petroleum segment. It derives the majority of its revenue from retail and wholesale distribution of fuel.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.